Natalie Penn, MD
Gastroenterology · Williamsville, NYNPI 1588152706
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 223 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Johnson & Johnson at 54.8% of the total.
Across 223 payments — averaging $11.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- AbbVie$364
- Takeda Pharmaceuticals U.S.A., Inc.$125
- Regeneron Healthcare Solutions, Inc.$71
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$70
- Sanofi$65
- plus $464 from 14 others
What the payments were for
- Food & beverage$2,555100%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 170 | $1,406 |
| AbbVie | 16 | $364 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $125 |
| Regeneron Healthcare Solutions, Inc. | 3 | $71 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $70 |
| Sanofi | 2 | $65 |
| Pfizer | 3 | $63 |
| QOL Medical, LLC | 3 | $63 |
| Celltrion USA Inc. | 2 | $52 |
| Gilead | 3 | $46 |
| Ardelyx, Inc. | 2 | $45 |
| Blueprint Medicines Corporation | 1 | $34 |
| Ipsen Biopharmaceuticals, Inc | 1 | $26 |
| Braintree Laboratories, Inc. | 1 | $24 |
| Madrigal Pharmaceuticals | 1 | $23 |
| Novo Nordisk | 1 | $20 |
| Merck | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
How this compares
$2,566 in reported general payments places this provider in the 55th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole | 73 | $1,037 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 25 | $472 |
| Pantoprazole Sodium | 31 | $415 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 18 | $283 |
| Ondansetron OdtOndansetron | 40 | $69 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Williamsville
- Maya SrivastavaWilliamsville$1.8M
- Ahmad KadhimWilliamsville$155K
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Melissa PalmerPlainview$1M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
- Jean Frederick ColombelNew York$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.